{
    "symbol": "BNR",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-31 12:42:06",
    "content": " And in terms of our pharmaceutical -- pharma business, the chain of (ph) growth continued in Q1, with over 300% year-over-year backlog progress and RMB59 million new contract value, which was 125% year-over-year growth. By segments, revenue growth was led by in-hospital, which grew 69% year-over-year, which again accelerated growth rate from the fourth quarter last year, which saw a year-over-year growth rate of 25%. One final question, so in April central lab revenues if they took it -- took a dip understandably so, but the in-hospital growth doubled to over 100% growth year-over-year compared to the prior month."
}